SOUTHEAST TECHINVENTURES INC — Department of Health and Human Services STTR Phase I: DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new pat
SOUTHEAST TECHINVENTURES INC — STTR Phase I award from Department of Health and Human Services.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Solicitation
- PA13-235
- NAICS
- —
- Place of performance
- NC
- Period
- —
Description
DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principal cause of treatment failure is chemotherapy resistance, despite an initial complete remission rate of 65%. Thelong-term goal of this STTR project is to develop a new drug for AML treatment that shows high efficacy in relapsed or refractory AML. F10 is a rationally designed molecule incorporating5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP), the active metabolite of 5-fluorouracil (5-FU) chemotherapy. Studies using human and murine AML cell lines have shown that F10 has strong potency against subtypes of AML with poor clinical prognosis. The focus of these proposed studies is to establish the efficacy of